NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

but others will be doing the work and sharing the income for every batch of DCVax-L that's made.

Gary, what others will be doing the work and sharing the income for every batch of DCVax-L that's made? According to NWBO, they will NOT be hiring any other third party to sell and market DCVAXL. Please read the 10K text I added.

the sale of the first batch of DCVax-L should more than pay for it

what sales will NWBO profit from Gary? Why are you and a couple of others just blandly ignoring the 10K text? NWBO just clearly stated that they are NOT able to sell and market DCVAXL. Also, they said that at the same time, no third parties will be able to sell and market DCVAXL for these third parties will have to be trained by NWBO which, according to NWBO, they are not able to do.

So why you then go on about NWBO or its third-party handler selling DCVAXL where NWBO said they will NOT be doing that is beyond me. I call that truly incredible cognitive dissonance from diehard lNWBO longs that still can not handle the reality that NWBO is NOT going to be an independent biotech. They will be bought Gary and with that, the problem of selling and marketing DCVAXL will be resolved.

As for the Annual Report, it's loaded with statement on the problems the company could encounte

Pffffff when shorts and bear say something that's no evidence of anyone slams them down because they are just talking about their rear end. But when NWBO itself is saying something that does not fit the grandeur fantasy expectation that NWBO is in fact at the limit of its capacity then its just boiler talk. Seriously? I take the 10K text at its face value I take what NWBO is saying seriously and have more belief in what NWBO is saying then NWBO groupies.

Our product candidates will require different marketing and sales methods and personnel than conventional therapeutic products. Also, we lack sales and marketing experience. These factors may result in significant difficulties in commercializing our product candidates.
The commercial success of any of our product candidates will depend upon the strength of our sales and marketing efforts. We do not have a marketing or sales force and have no experience in marketing or sales of products like our lead product, DCVax-L for GBM, or our additional product, DCVax-Direct. To fully commercialize our product candidates, we will need to recruit and train marketing staff and a sales force with technical expertise and ability to manage the distribution of our DCVax-L for GBM. As an alternative, we could seek assistance from a corporate partner or a third-party services firm with a large distribution system and a large direct sales force. However, since our DCVax products are living cell, immune therapy products, and these are a fundamentally new and different type of product than are on the market today, we would still have to train such partner’s or such services firm’s personnel about our products and would have to make changes in their distribution processes and systems to handle our products. We may be unable to recruit and train effective sales and marketing forces or our own, or of a partner or a services firm, and/or doing so may be more costly and difficult than anticipated. Such factors may result in significant difficulties in commercializing our product candidates, and we may be unable to generate significant revenues.